Intuitive Surgical: The Moat Is Intact, but the Share Price Has Already Pulled Forward Future Cash Flow

Intuitive Surgical (NASDAQ: ISRG) Stock Deep Research Report

A01 | Reading Path | Decision First, Proof Second

This report is a complete long-form report for investors, not a standalone investment decision summary or a standalone data repository. The first half addresses the investment decision layer first: current action, key variables, position sizing constraints, and reverse falsification. The second half preserves the deep proof layer: revenue bridge, business mechanisms, financial profile, ROIC, moat, competition, China, valuation, peer opportunity cost, and quarterly tracking.

The reading sequence is simple:

1. First read the “One-Page Investment Decision Card” and the “7 master control variables” to clarify why the current stance is watchlist/small position rather than a large position.
2. Then read “Business Demand” and “Revenue Engine” to understand why ISRG is not an ordinary equipment company.
3. After that, move into the 70-chapter deep proof layer to verify whether each conclusion is supported by financials, competition, moat, and valuation.

A02 | One-Page Investment Decision Card

ISRG remains a high-quality company, but it is not currently an unconditional core buy. The main chain has not broken: procedure volume, I&A, service, and recurring revenue are still moving in sync; competitors have not yet entered L4 recurring revenue capture in the United States; pressure in China has been established on the systems side, but it still cannot be directly extrapolated into a collapse of the global recurring revenue moat. What truly constrains position sizing is price and cash flow validation: the 2026E FCF/share jump has not yet been fully proven by the normalized Q1 level, while peers such as BSX, DHR, and SYK offer higher starting points for normalized FCF.

One-sentence action:

ISRG is a high-quality compounding asset, but it is currently more suitable for watchlist status or a small trial position;
it should move into a higher position only when the price is better or FCF quality is proven by Q2/Q3.

One-Page Quarterly Update Dashboard

This table will be updated on a rolling basis like a financial statement. After each earnings report, first add the new quarter horizontally, then judge whether “the main chain is stronger, cash flow quality has been validated, competition has advanced, and position sizing action needs to change.”

A03 | Investment Judgment Framework

When analyzing ISRG, one cannot look only at a single composite judgment. Company quality, moat, financial validation, and investment attractiveness must be separated; otherwise it is very easy to mistake a “good company” for a “good investment.”

How to read it:

• Position sizing action should look only at the investment attractiveness score, not directly at the company quality score.
• When company quality is high but valuation is high, FCF is unvalidated, and peer odds are better, the only appropriate stance is a small position or watchlist status.
• China risk, competitor L4, FCF quality, and peer opportunity cost will simultaneously constrain the position sizing ceiling.

A04 | 8 Core Investment Questions

Minimum sufficient explanation:

ISRG's value comes from post-install procedure volume, consumables, service, and per-share cash flow.
This chain has not broken for now, so company quality remains high.
But the current price requires FCF/share to keep stepping up, while Q1 only partially validated that;
at the same time, peers offer a higher cash flow starting point.
Therefore, the current stance is watch/small position, not a large position.